Valinor | $13,000,000 | (Dec 12, 2025)
Keeper | $4,000,000 | (Dec 12, 2025)
Cyphlens | $3,800,000 | (Dec 12, 2025)
Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
OnCorps AI | $55,000,000 | (Dec 12, 2025)
conveyd | $3,345,837 | (Dec 12, 2025)
Ritten | $35,000,000 | (Dec 12, 2025)
Safebooks AI | $15,000,000 | (Dec 12, 2025)
Double (1) | $6,500,000 | (Dec 12, 2025)
Yonda | $15,000,000 | (Dec 12, 2025)
Medra | $52,000,000 | (Dec 12, 2025)
Cynch AI | $9,000,000 | (Dec 12, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)